More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$155449737
EPS
-2.35
P/E ratio
--
Price to sales
1.02
Dividend yield
--
Beta
1.132555
Previous close
$3.80
Today's open
$3.80
Day's range
$3.27 - $3.86
52 week range
$2.40 - $8.77
show more
CEO
Masoud Toloue
Employees
471
Headquarters
Billerica, MA
Exchange
NASDAQ Global Market
Shares outstanding
47105981
Issue type
Common Stock
Healthcare
Biotechnology & Life Sciences
Quanterix Appoints Industry Veteran Geoff Albrecht as Senior Vice President and General Manager of Diagnostics
BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (Nasdaq: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced the appointment of Geoff Albrecht as Senior Vice President and General Manager of Diagnostics. This strategic hire underscores Quanterix's commitment to transforming its Diagnostics opportunity into a key component of the company's future growth strategy. Starting with Alzheimer's Disease Diagnostics, Al.
Business Wire • Jun 4, 2026

Quanterix To Participate in the Goldman Sachs 47th Annual Global Healthcare Conference
BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (Nasdaq: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced that senior management will participate in the Goldman Sachs 47th Annual Global Healthcare Conference being held in Miami, FL from June 8-10, 2026. Chief Executive Officer Everett Cunningham will engage in a fireside chat at 1:20 pm ET on Tuesday, June 9, during which he will provide an update on the Com.
Business Wire • Jun 3, 2026

Quanterix Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (“Quanterix” or the “Company”) (NASDAQ: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced that on May 15, 2026, an inducement grant (the “Inducement Grant”) was made to Anthony Catalano in connection with the commencement of his employment as the Chief Operating Officer of the Company. The Inducement Grant consists of restricted stock units (“RSUs”) covering 141.
Business Wire • May 26, 2026

Quanterix Announces Planned Transition of Chief Financial Officer
BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (Nasdaq: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced that Vandana Sriram, its Chief Financial Officer (“CFO”) will depart the Company. A search for her successor is ongoing, and Ms. Sriram will continue as CFO through June 15, 2026, to ensure continuity and a successful transition. "Vandana has made impactful contributions to Quanterix since joining the Co.
Business Wire • May 12, 2026

Quanterix Corporation (QTRX) Q1 2026 Earnings Call Transcript
Quanterix Corporation (QTRX) Q1 2026 Earnings Call Transcript
Seeking Alpha • May 6, 2026

Quanterix Releases Financial Results for the First Quarter of 2026
BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced financial results for the first quarter ended March 31, 2026. “We continue to make progress toward achieving cash flow breakeven as we move into a phase of growth now that we have captured the cost synergies from the Akoya acquisition,” said Everett Cunningham, President & CEO of Quanterix. “As part.
Business Wire • May 6, 2026

Quanterix Corporation (QTRX) Reports Q1 Loss, Lags Revenue Estimates
Quanterix Corporation (QTRX) came out with a quarterly loss of $0.39 per share versus the Zacks Consensus Estimate of a loss of $0.31. This compares to a loss of $0.53 per share a year ago.
Zacks Investment Research • May 6, 2026

Lucent Diagnostics Announces Collaboration with Tempus to Integrate Blood-Based Alzheimer's Biomarker Testing into Clinical Workflows
BILLERICA, Mass.--(BUSINESS WIRE)--Lucent Diagnostics, a brand of Quanterix Corporation (NASDAQ: QTRX), today announced a collaboration with Tempus AI Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, to broaden access to a novel blood-based biomarker panel designed to improve detection accuracy for Alzheimer's disease. Through the agreement, Tempus AI will build a Tempus Next care gap program for Alzheimer's disease blood-based biomarker testing.
Business Wire • May 6, 2026

Quanterix To Report First Quarter 2026 Financial Results on May 6, 2026
BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (Nasdaq: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced that it will host a conference call on Wednesday, May 6, 2026, at 4:30 p.m. E.T., to discuss its first quarter 2026 financial results. Quanterix will issue a press release regarding its first quarter 2026 financial results prior to the conference call on Wednesday, May 6, 2026, after the market closes. T.
Business Wire • Apr 24, 2026

AidaBREAST™ Multi-Omic Assay Demonstrates Spatial Proteomics for Clinical Oncology
LAGUNA HILLS, Calif. & BILLERICA, Mass.--(BUSINESS WIRE)--PreludeDx® and Quanterix Corporation (Nasdaq: QTRX) today highlighted that AidaBREAST™, the first multi-omic assay to predict both locoregional recurrence risk and radiation therapy benefit in early-stage invasive breast cancer, was developed on Akoya PhenoImager® HT platform using Opal™ chemistry. This marks a significant milestone in the clinical translation of spatial proteomics. The validation of AidaBREAST included 922 hormone recep.
Business Wire • Apr 17, 2026

¹ Disclosures

Open an M1 investment account to buy and sell Quanterix Corporation commission-free¹. Build wealth for the long term using automated trading and transfers.